{"name":"Amylyx Pharmaceuticals","slug":"amylyx","ticker":"AMLX","exchange":"NASDAQ","domain":"amylyx.com","description":"Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Justin Klee & Joshua Cohen (Co-CEOs)","sector":"Neuroscience / ALS","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$220M","metrics":{"revenue":380786000,"revenueGrowth":1612.9,"grossMargin":0,"rdSpend":90404000,"netIncome":-144735000,"cash":332645000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2022-01-01","label":"Relyvrio first approved","drug":"Relyvrio","drugSlug":"taurursodiol","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Relyvrio patent cliff ($1.3B at risk)","drug":"Relyvrio","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AMX0114","genericName":"AMX0114","slug":"amx0114","indication":"Other","status":"phase_1"},{"name":"Relyvrio","genericName":"TAURURSODIOL","slug":"taurursodiol","indication":"Amyotrophic lateral sclerosis","status":"marketed"},{"name":"AMX0035","genericName":"AMX0035","slug":"amx0035","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_3"}]}],"pipeline":[{"name":"AMX0114","genericName":"AMX0114","slug":"amx0114","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Relyvrio","genericName":"TAURURSODIOL","slug":"taurursodiol","phase":"marketed","mechanism":"Relyvrio works by inhibiting the enzyme phospholipase A2, which is involved in the breakdown of lipids in the brain.","indications":["Amyotrophic lateral sclerosis"],"catalyst":""},{"name":"AMX0035","genericName":"AMX0035","slug":"amx0035","phase":"phase_3","mechanism":"AMX0035 is a fixed-dose combination of sodium phenylbutyrate and taurursodiol that reduces neuroinflammation and protects motor neurons by stabilizing mitochondrial function and reducing ER stress.","indications":["Amyotrophic lateral sclerosis (ALS)"],"catalyst":""}],"recentEvents":[{"date":"2023-06-16","type":"regulatory","headline":"Amylyx Pharmaceuticals Announces FDA Approval of Relyvrio for ALS","summary":"The FDA approved Relyvrio for the treatment of ALS, marking a significant milestone for the company.","drugName":"Relyvrio","sentiment":"positive"},{"date":"2022-11-15","type":"earnings","headline":"Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results","summary":"The company reported revenue of $13.4 million for the third quarter of 2022, exceeding expectations.","drugName":"","sentiment":"positive"},{"date":"2022-08-09","type":"deal","headline":"Amylyx Pharmaceuticals Announces Collaboration with the ALS Association","summary":"The company partnered with the ALS Association to support ALS research and patient advocacy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-30","type":"trial","source":"simplywall.st","summary":"A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment - simplywall.st","headline":"A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNblMtWUJ6bGxDS01FVzJNS2E3QVNpenY2aUZfeGNCZFROZTY4cC1xLVdWZ0pYa3RONTZYM1lZU01BZTRTWkZFeHVKbjl2a3lCdEwtWlBHRVZKRXNVaDE5Qmt4TXA1Y2lSR2p2NjNsUjdhYWtIT0tDVC1zd1NmeVo3blFtdWw2dldGcWx2cDBNTWJtYXFvQzNFVzFrNjdQTk40Z0lVQVVOcnBPeFFXWnpWYUtXb3lMQ3hVUmlSTUdn?oc=5","date":"2026-01-20","type":"pipeline","source":"Investing.com","summary":"Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock - Investing.com","headline":"Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPeDFWQV9jS3FvRUFLODlmZ0YyZ0F2dl9waGpRZXhSY1dEOUJucVBVM1VZT2gtVEczamNJV1Bad2pSRzdBMHFlRXpWVzJGcHNZaXlta1pfNUhUcXcwZV83UGVUQzREc21fa255WmczWVpiNVlMYjlaMUYxSFdoZnFVQUQtWkk4cC1rQXZuTy1CbmpiTDNSamZFVDlwaU1iMnNjeDhSeU1JaGUzOFB1dEs1VQ?oc=5","date":"2026-01-20","type":"pipeline","source":"Investing.com","summary":"Amylyx pharma co-CEO Cohen sells $1.87m in shares - Investing.com","headline":"Amylyx pharma co-CEO Cohen sells $1.87m in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNNjNwcF92bkg3bHU2c0o5QUVwRl9iMFExTjczbW9jX3h3cDhranZuelgzLTM0OWNhcFV4OWQzblJhenhDN2NZdW9aUldqQlNzYjY4allHRXRVRjNFU0x5bUJQS3FkVmw3N2c3XzVJVWRsX2tueXRmNVU1U01RVEtjRUFmZ3pvRmdQanAzOC0yd05QSlNUT3lIclBpMlprUjNDZDFuaHpEV0ZpSURyTmc5MmJfd1VmN0dQdnlBd1ZnNWJLQmdrcmFMcUMwMk1FWjVxN2hCZHgxTGotWUFRTWc?oc=5","date":"2025-10-30","type":"earnings","source":"Business Wire","summary":"Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire","headline":"Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNdTVrX0ZjNmVWaHRzLWZpR0pKNUw4ckxmZTFiRnNGXzlmUzBjLWNuZnJoLUlfTEM3dVh5bjJiNndsWmJOVXRHckNKSE5IWWFVaEd5SUFWN2hqNzBaU2FuM3A3bUxteXZBZ2puNUlsd092UlpfdXYxZ250VElRTnV1bnZ0eERuVmVBWldjRkFTOWExaEZBNTlJYmR2ekVtTVUwbkthaElsWUxranpOa3k5aFBqSE5ZdUU4MzFtU01OTDJIc1JHV0pxQ2NJa3JuQlY2YTZLXy1TRkxjc2J2aWZYN1ZMclRlZUd5N0J4cWd2a0tFQQ?oc=5","date":"2025-09-10","type":"pipeline","source":"Business Wire","summary":"Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock - Business Wire","headline":"Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-01","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation - simplywall.st","headline":"Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRVRSUlBvUDdDVmVIOTZ5R2pUZ3dYeEZCRTJDR0JEY0oxMGl0MlMxck1Rd1QxNllDT2Exdy1ONVZWZV9pS0lwa0RqYnE4ZWlpYkNOY2tHUWdFd0hRNklVclRZTlZxVVZfMG1CNUR4QjBrY01OcmtDR0p3dXJZdVhNcS16SmpmOHZHTk1lRFV0blFHaElqTHpCUW10Qk9Wd2FzUGR3aTVlQ1lPSDY3ZHd1elVudy1QU0VVTEJ5QzAtSlZyaUNfNFBOTW5nZ1Z3RTQ2djRxbTBUMA?oc=5","date":"2025-08-27","type":"trial","source":"Reuters","summary":"Amylyx to stop development of rare brain disorder drug after trial failure - Reuters","headline":"Amylyx to stop development of rare brain disorder drug after trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNVE0tYnRzXzFrRW1OMW9GRHdLd1hZcTZmOHRLc004LTZ1bGhDUERhODMxa3JiRk1uYmdzS1l1Y0ZpUnZIeHNCM2JBTjhoeDdfYUNtUXFSYzJhWnhfM2c5blRkalNHSDRIbkNiTzNOSmgxME1XR2xwMWpjVWQ4b2FzUEp1dGllelVoLUhpRDBIRU9pRGl4UWJRRUV3TjA2OURkalFwLTJWbFZ0b0RzOU1kbE56UmdxTWRKU0RhZU5xU0RuMEU?oc=5","date":"2025-08-07","type":"earnings","source":"Business Wire","summary":"Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - Business Wire","headline":"Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOM3hoemVFQ3F2Z3lxZmNheGVQaVlxWTBnQnFmbVRhX05GRkhQZC10THBMcTUxT1FwQnh3Y21TclFibnh4UE92dnhNTzRpYVRlTGVIQktya1ZlR0d1Ukd1RklOMWM2NkVPdVlSck9ORTRTbmpoMDNpN0QweTlBcWlrWndpLW5sREpqUlMwQndUaXhIODlmU0JsWjBPZw?oc=5","date":"2025-07-15","type":"trial","source":"Yahoo Finance","summary":"Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Yahoo Finance","headline":"Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNMnV4MlJXSWFJaTAzQnZrQ2ZMOURfbVZMYU9uZVE2em9zYnhPdkR2Y3Z1dHVJSnNhZTNjWWdWSExfVUhlSjdsSUZObm5hVnJZLVJKRGpUTGwxa1Q1Smo5aWVjc3dnTTR3TjNocnlhRUhLMGRQbnRrZU5uaHpmYUJiZFJPX080R0tSdFBsWWhSSHJKa0lzZFpGbA?oc=5","date":"2025-06-27","type":"pipeline","source":"The Motley Fool","summary":"Why Shares in Amylyx Pharmaceuticals Soared This Week - The Motley Fool","headline":"Why Shares in Amylyx Pharmaceuticals Soared This Week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9SOXIyd0diOG41VGd5aDEwbjIzdEVfTFdvY2txSm1mZTdwUnR5SV83Ry1OOTdjbUIyZ2d4QU45eUlPNGlJSzRKX0tkQ2FZTlZL?oc=5","date":"2024-03-08","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOc18yenczMjQtdk1IdFhJUUhDTERpQmo2M2VEZVJHN0RxZ0RoZDFlT2hyYWJZX2g3RGNaa1JUTUdqNUo1QXhPZElkM2ViNEZSVmtHbTI2ZnJLNTNKYVZqc2hlOFdaNnMySXkzcVZfYUJNTzVjcnRWaHFUelV0Y2VKSVdPRy1kck1qX1IyYWZLcVZMbXJo?oc=5","date":"2022-03-30","type":"regulatory","source":"Barron's","summary":"FDA Advisors Narrowly Oppose Amylyx’s ALS Drug - Barron's","headline":"FDA Advisors Narrowly Oppose Amylyx’s ALS Drug - Barron's","sentiment":"neutral"}],"patents":[{"drugName":"Relyvrio","drugSlug":"cysteamine-bitartrate-and-phenylbutyrate","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1300000000}],"drugCount":3,"phaseCounts":{"phase_1":1,"marketed":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Cytokinetics","Sarepta Therapeutics"],"therapeuticFocus":["Neurodegenerative diseases","Amyotrophic lateral sclerosis (ALS)"],"financials":{"source":"sec_edgar","revenue":380786000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":380786000,"period":"2023-12-31"},{"value":22230000,"period":"2022-12-31"},{"value":22230000,"period":"2022-12-31"},{"value":285000,"period":"2021-12-31"},{"value":285000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":90404000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-144735000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":332645000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}